View DividendRafarma Pharmaceuticals マネジメントマネジメント 基準チェック /14現在、CEO に関する十分な情報がありません。主要情報 最高経営責任者n/a報酬総額CEO給与比率n/aCEO在任期間no dataCEOの所有権n/a経営陣の平均在職期間データなし取締役会の平均在任期間6.1yrs経営陣の近況お知らせ • Sep 19Rafarma Pharmaceuticals, Inc. Appoints Ilia Shpurov as Chairman of the BoardRafarma Pharmaceuticals, Inc. announced the appointment of Ilia Shpurov as Chairman of the Board. Mr. Shpurov has a long history of technological developments, patents and entrepreneurial achievements in biotech. Most recently Mr. Shpurov purchased Kraspharma in 2008 and has built it into one of the top pharmaceutical companies in Russia. Mr. Shpurov also created the Pereslavsky Group technology park in 2004. Mr. Shpurov is also Vice President of the International Congress of Industrialists and Entrepreneurs. Mr. Shpurov brings unique experience to the board of directors and is a well-known businessman throughout Europe. His expertise in pharmaceutical growth will power Rafarma toward its goals of worldwide growth and profitability.すべての更新を表示Recent updatesお知らせ • Jan 31Rafarma Pharmaceuticals, Inc. Secures Joint Venture Agreement with the Pharmaceutical Industry Development Agency of UzbekistanRafarma Pharmaceuticals, Inc. announced its joint venture with the entity known as The Pharmaceutical Industry Development Agency of Uzbekistan. Together the two organizations will produce medicines for use by public health institutions in the Republic of Uzbekistan. This will entail the acquisition of real property (10 hectares in the established Innovative Scientific Production Pharmaceutical Cluster known as “Tashkent Pharma Park”) and construction of a physical plant on the premises. Projected costs are currently at $82,000,000. Both parties will be tasked with developing a timetable for project completion and implementation (projected time table 2021-2025). Rafarma will supply experts in their respective fields, oversee construction, and supply necessary equipment. The Pharmaceutical Industry Development Agency will be responsible for obtaining the necessary registration and certification of all future medicines produced by the partnership, and negotiating contracts with the health sector of the Republic of Uzbekistan.お知らせ • Dec 17Vaccines Lab Sdn Bhd Enters Master Strategic Joint Venture Agreement with Rafarma Pharmaceuticals IncVaccines Lab Sdn Bhd enters Master Strategic Joint Venture agreement with Rafarma Pharmaceuticals Inc.お知らせ • Dec 02Rafarma Pharmaceuticals, Inc. Signs a Joint Venture Agreement with Vaccines Lab SDN BHD of MalaysiaRafarma Pharmaceuticals, Inc. has signed a Joint Venture Agreement with Vaccines Lab SDN BHD of Malaysia. Under the terms of the agreement, Rafarma and Vaccines Lab with create a new jointly-operated vaccine facility in Indonesia to research, develop, conduct clinical trials and license for various in-demand vaccines to combat several viruses. The joint venture will combine the expertise of Vaccines Lab and RAFARMA with its PJSC Kraspharma (OJSC Krasfarma) and R. & D. Biocogency Laboratories Inc. Rafarma plans to continue to aggressively pursue vaccine development with joint venture partners worldwide.お知らせ • Oct 20R. & D. Biocogency Laboratories Inc. Ltd. completed the acquisition of an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA).R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on August 4, 2020. The majority control will be acquired by Biocogency upon completion of Biocogency’s transition to GAAP reporting standards and finalization of acquisition agreements. Rafarma Pharmaceuticals Approves Issuance of Majority of Preferred B shares, conferring voting Shares to Board Chairman Ilya Shpurov, toward the combination of its acquisition by R. & D. BIOCOGENCY LABORATORIES Group. R. & D. Biocogency Laboratories Inc. Ltd. completed the acquisition of an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on October 19, 2020.お知らせ • Sep 19Rafarma Pharmaceuticals, Inc. Appoints Ilia Shpurov as Chairman of the BoardRafarma Pharmaceuticals, Inc. announced the appointment of Ilia Shpurov as Chairman of the Board. Mr. Shpurov has a long history of technological developments, patents and entrepreneurial achievements in biotech. Most recently Mr. Shpurov purchased Kraspharma in 2008 and has built it into one of the top pharmaceutical companies in Russia. Mr. Shpurov also created the Pereslavsky Group technology park in 2004. Mr. Shpurov is also Vice President of the International Congress of Industrialists and Entrepreneurs. Mr. Shpurov brings unique experience to the board of directors and is a well-known businessman throughout Europe. His expertise in pharmaceutical growth will power Rafarma toward its goals of worldwide growth and profitability.お知らせ • Aug 06R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA).R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on August 4, 2020. The majority control will be acquired by Biocogency upon completion of Biocogency’s transition to GAAP reporting standards and finalization of acquisition agreements.CEORafarma Pharmaceuticals CEOがいない、あるいは彼らに関するデータがない。取締役名称ポジション在職期間報酬所有権Sergey BrusnitsinChief Financial Officer and Directorno dataデータなしデータなしAlexander AgeevSecretaryno dataデータなしデータなしBruno HornDirector11.8yrsデータなしデータなしSreco BojtDirectorno dataデータなしデータなしVladislav LaskavyMember of the Advisory Board6.1yrsデータなしデータなしIlya ShpurovChairman of the Board5.7yrsデータなしデータなしもっと見る6.1yrs平均在職期間経験豊富なボード: RAFAの 取締役会 は 経験豊富 であると考えられます ( 6.1年の平均在任期間)。View Ownership企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 15:46終値2026/05/22 00:00収益2012/03/31年間収益2012/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Rafarma Pharmaceuticals, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Sep 19Rafarma Pharmaceuticals, Inc. Appoints Ilia Shpurov as Chairman of the BoardRafarma Pharmaceuticals, Inc. announced the appointment of Ilia Shpurov as Chairman of the Board. Mr. Shpurov has a long history of technological developments, patents and entrepreneurial achievements in biotech. Most recently Mr. Shpurov purchased Kraspharma in 2008 and has built it into one of the top pharmaceutical companies in Russia. Mr. Shpurov also created the Pereslavsky Group technology park in 2004. Mr. Shpurov is also Vice President of the International Congress of Industrialists and Entrepreneurs. Mr. Shpurov brings unique experience to the board of directors and is a well-known businessman throughout Europe. His expertise in pharmaceutical growth will power Rafarma toward its goals of worldwide growth and profitability.
お知らせ • Jan 31Rafarma Pharmaceuticals, Inc. Secures Joint Venture Agreement with the Pharmaceutical Industry Development Agency of UzbekistanRafarma Pharmaceuticals, Inc. announced its joint venture with the entity known as The Pharmaceutical Industry Development Agency of Uzbekistan. Together the two organizations will produce medicines for use by public health institutions in the Republic of Uzbekistan. This will entail the acquisition of real property (10 hectares in the established Innovative Scientific Production Pharmaceutical Cluster known as “Tashkent Pharma Park”) and construction of a physical plant on the premises. Projected costs are currently at $82,000,000. Both parties will be tasked with developing a timetable for project completion and implementation (projected time table 2021-2025). Rafarma will supply experts in their respective fields, oversee construction, and supply necessary equipment. The Pharmaceutical Industry Development Agency will be responsible for obtaining the necessary registration and certification of all future medicines produced by the partnership, and negotiating contracts with the health sector of the Republic of Uzbekistan.
お知らせ • Dec 17Vaccines Lab Sdn Bhd Enters Master Strategic Joint Venture Agreement with Rafarma Pharmaceuticals IncVaccines Lab Sdn Bhd enters Master Strategic Joint Venture agreement with Rafarma Pharmaceuticals Inc.
お知らせ • Dec 02Rafarma Pharmaceuticals, Inc. Signs a Joint Venture Agreement with Vaccines Lab SDN BHD of MalaysiaRafarma Pharmaceuticals, Inc. has signed a Joint Venture Agreement with Vaccines Lab SDN BHD of Malaysia. Under the terms of the agreement, Rafarma and Vaccines Lab with create a new jointly-operated vaccine facility in Indonesia to research, develop, conduct clinical trials and license for various in-demand vaccines to combat several viruses. The joint venture will combine the expertise of Vaccines Lab and RAFARMA with its PJSC Kraspharma (OJSC Krasfarma) and R. & D. Biocogency Laboratories Inc. Rafarma plans to continue to aggressively pursue vaccine development with joint venture partners worldwide.
お知らせ • Oct 20R. & D. Biocogency Laboratories Inc. Ltd. completed the acquisition of an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA).R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on August 4, 2020. The majority control will be acquired by Biocogency upon completion of Biocogency’s transition to GAAP reporting standards and finalization of acquisition agreements. Rafarma Pharmaceuticals Approves Issuance of Majority of Preferred B shares, conferring voting Shares to Board Chairman Ilya Shpurov, toward the combination of its acquisition by R. & D. BIOCOGENCY LABORATORIES Group. R. & D. Biocogency Laboratories Inc. Ltd. completed the acquisition of an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on October 19, 2020.
お知らせ • Sep 19Rafarma Pharmaceuticals, Inc. Appoints Ilia Shpurov as Chairman of the BoardRafarma Pharmaceuticals, Inc. announced the appointment of Ilia Shpurov as Chairman of the Board. Mr. Shpurov has a long history of technological developments, patents and entrepreneurial achievements in biotech. Most recently Mr. Shpurov purchased Kraspharma in 2008 and has built it into one of the top pharmaceutical companies in Russia. Mr. Shpurov also created the Pereslavsky Group technology park in 2004. Mr. Shpurov is also Vice President of the International Congress of Industrialists and Entrepreneurs. Mr. Shpurov brings unique experience to the board of directors and is a well-known businessman throughout Europe. His expertise in pharmaceutical growth will power Rafarma toward its goals of worldwide growth and profitability.
お知らせ • Aug 06R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA).R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on August 4, 2020. The majority control will be acquired by Biocogency upon completion of Biocogency’s transition to GAAP reporting standards and finalization of acquisition agreements.